Table of Content - Fascioliasis Market

Fascioliasis is an infectious disease usually caused by Fasciola hepatica, also called as the common liver fluke or the sheep liver fluke. Fascioliasis is caused by two fasciola species, the main species Fasciola hepatica, and another related species Fasciola gigantica, which also can infect people. Fasciola gigantica has been found in some tropical areas such as Australia, China. Fascioliasis is found where sheep or cattle are reared. People are infected with Fasciola when the parasite is accidentally ingested (swallowed) through raw watercress or other contaminated freshwater plants, and also by drinking contaminated water. Other ways include by eating vegetables that were washed or irrigated with contaminated water. Fasciola infection can be prevented by not eating raw watercress and other water plants, especially from endemic grazing areas. Some people feel sick during the early stage of infection, while immature flukes migrate from the intestine through the abdominal cavity and liver. Fasciola infection is both treatable and preventable.

Market Dynamics

Increasing adoption of inorganic strategies such as product approvals by the U.S. Food and Drug Administration is expected to drive the global fascioliasis market growth over the forecast period. For instance, in February 2019, Novartis AG, a pharmaceutical company, announced that they had received an approval from the U.S.Food and Drug Administration for triclabendazole (Egaten) for the treatment of fascioliasis in patients aged 6 years and older. The approval of triclabendazole in the U.S. is expected to facilitate drug licensing and import to endemic countries, to provide a help for the sufficient availability of the drug when needed.

Key features of the study:

This report provides an in-depth analysis of the global fascioliasis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fascioliasis market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, AMGIS Lifescience Ltd., Romark, AbbVie Inc., Merck KGaA, AdvaCare Pharma, Intas Pharmaceuticals Ltd., Procyon Life Sciences, Adroit Pharmachem Pvt Ltd., Sun Pharmaceutical Industries Ltd., RV Lifesciences Limited, Grampus Laboratories, and Janssen Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global fascioliasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fascioliasis market

Detailed Segmentation:

Global Fascioliasis Market, By Drug:
- Triclabendazole
- Albendazole
- Nitazoxanide
Global Fascioliasis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Fascioliasis Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Novartis AG*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AMGIS Lifescience Ltd.
- Romark
- AbbVie Inc.
- Merck KGaA
- AdvaCare Pharma
- Intas Pharmaceuticals Ltd.
- Procyon Life Sciences
- Adroit Pharmachem Pvt Ltd.
- Sun Pharmaceutical Industries Ltd.
- RV Lifesciences Limited
- Grampus Laboratories
- Janssen Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Regulatory Guidelines
- Product launches
- Key Development
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
Global Fascioliasis Market– Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
Global Fascioliasis Market, By Drug, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Triclabendazole
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Albendazole
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Nitazoxanide
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Global Fascioliasis Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Hospital Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
  - Overview
  - Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
Global Fascioliasis Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, For Regions, 2017–2030
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AMGIS Lifescience Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Romark
  - Company Highlight
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck KGaA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AdvaCare Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Intas Pharmaceuticals Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Procyon Life Sciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Adroit Pharmachem Pvt Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- RV Lifesciences Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Grampus Laboratories
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Janssen Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
Section
- Research Methodology
- About Us

*Browse 26 market data tables and 24 figures on "Global Fascioliasis Market” - forecast to 2030

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount